Copyright
©The Author(s) 2020.
World J Gastroenterol. Oct 14, 2020; 26(38): 5874-5883
Published online Oct 14, 2020. doi: 10.3748/wjg.v26.i38.5874
Published online Oct 14, 2020. doi: 10.3748/wjg.v26.i38.5874
Table 1 Sociodemographics, substance use characteristics and blood parameters of anti-hepatitis C virus positive patients in an Opioid Treatment Program
| Anti-HCV positive, n = 336, n (%) | |
| Female, n (%) | 57 (17.0) |
| Age (yr), median (IQR) | 46 (41-50) |
| Time in OTP (yr), median (IQR) | 15.3 (5.6-19.2) |
| Opiate agonists | |
| Methadone | 331 (98.5) |
| Buprenorphine | 5 (1.5) |
| Antecedent of injection drug use (n = 326) | 282 (86.5) |
| History of incarceration (n = 291) | 158 (54.3) |
| Current substance use (last month) (n = 213), n (%) | |
| Alcohol | 101 (47.2) |
| Cannabis | 88 (41.3) |
| Cocaine | 68 (31.9) |
| Heroin | 49 (23.0) |
| Blood parameters | |
| Leucocyte (× 109/L) (n = 298) | 6.7 (5.3-8.6) |
| Lymphocyte (× 109/L) (n = 296) | 2.2 (1.5-2.8) |
| Platelets (× 109/L) (n = 295) | 181 (138-232) |
| Hemoglobin (mg/dL) (n = 296) | 14.3 (13-15.1) |
| AST (U/L) (n = 284) | 31 (21-52) |
| ALT (U/L) (n = 252) | 30 (18-52.5) |
| GGT (U/L) (n = 242) | 44.5 (25-89) |
| Total bilirubin (mg/dL) (n = 238) | 0.5 (0.4-0.7) |
| Total cholesterol (mg/dL) (n = 210) | 168.5 (144-194) |
| HIV infection, n (%) (n = 334) | 160 (47.9) |
- Citation: Sanvisens A, Rivas I, Faure E, Espinach N, Hernandez-Rubio A, Majó X, Colom J, Muga R. Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study. World J Gastroenterol 2020; 26(38): 5874-5883
- URL: https://www.wjgnet.com/1007-9327/full/v26/i38/5874.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i38.5874